title: Electroporation therapy for T1 and T2 oral tongue cancer.
abstract: CONCLUSIONS
  Electroporation therapy appears to be a safe treatment achieving excellent local tumor control and very good functional results in our study and it should be further clinically evaluated.
  
  
  OBJECTIVE
  The objectives of this study were to assess local tumor control, survival, and effects on speech and eating after treatment of tongue cancer with electroporation therapy, a new local therapeutic modality. In this approach intracellular accumulation of a chemotherapeutic agent is achieved by using a locally applied electrical field.
  
  
  METHODS
  Fifteen patients with primary T1 and T2 oral tongue cancer were treated with electroporation therapy with intratumorally administered bleomycin. Postoperative radiotherapy was performed when the tumor infiltration was 5 mm or more. The follow-up time was 24 months for the surviving patients and 20.4 months overall. The effects on eating and speech were assessed using the PSS-HN scale and voice recordings.
  
  
  RESULTS
  No local recurrence was recorded in any patient during the follow-up. Three patients died, two from progressive regional disease. Of the 12 surviving patients, 2 patients had regional recurrence and 10 patients including the 5 patients treated with EPT alone were tumor-free both locally and regionally at the last follow-up. The functional outcome for speech and eating were very good.
authors.affiliation: Department of Otolaryngology, Örebro University Hospital, Sweden. fredrik.landstrom@orebroll.se
authors.forename: Fredrik J
authors.initials: FJ
authors.lastname: Landström
authors.forename: Christer O S
authors.initials: CO
authors.lastname: Nilsson
authors.forename: Johan A
authors.initials: JA
authors.lastname: Reizenstein
authors.forename: Kent
authors.initials: K
authors.lastname: Nordqvist
authors.forename: Gun-Britt
authors.initials: GB
authors.lastname: Adamsson
authors.forename: A Lennart
authors.initials: AL
authors.lastname: Löfgren
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D053672:Electrochemotherapy / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D037981:Neck Dissection; D009367:Neoplasm Staging; D015996:Survival Rate; D014062:Tongue Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery
chemical_list: D000903:Antibiotics, Antineoplastic; D001761:Bleomycin